Farnesyltransferase Inhibitor Patient Selection via Biomarker Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating cancer with farnesyltransferase inhibitors (FTIs) lack effectiveness in predicting patient responsiveness and selecting appropriate patients, leading to variable treatment outcomes for conditions like peripheral T-cell lymphoma, Myelodysplastic syndrome, and Acute Myeloid Leukemia.
Innovation Solution
Administering a therapeutically effective amount of FTIs, such as tipifarnib, to patients based on specific biomarkers like absolute neutrophil count, blood-to-marrow blast ratio, and CXCL12/CXCR4 expression levels, to target bone marrow homing of myeloid cells and enhance treatment responsiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If FTIs are administered to all cancer patients, then broader treatment coverage is achieved, but treatment effectiveness varies due to inability to predict patient responsiveness
Solution Approach 1:
The patent applies preliminary action by determining bone marrow homing status (through biomarker analysis or empirical criteria) before administering FTIs. This pre-screening approach identifies patients most likely to respond to treatment, ensuring that FTIs are given only to appropriate candidates rather than all cancer patients, thereby resolving the contradiction between broad coverage and effective treatment.
2Ease of operation
If FTI treatment is expanded to more patient populations, then treatment accessibility increases, but variable responsiveness across patients reduces overall therapeutic efficacy
Solution Approach 1:
The patent implements preliminary determination of bone marrow homing status using accessible criteria (biomarker analysis or empirical patient characteristics) before initiating FTI therapy. This approach maintains treatment accessibility by using straightforward assessment methods while simultaneously improving therapeutic efficacy by identifying the specific patient subset most likely to benefit, thus resolving the contradiction between ease of operation and reliability.
Data Source
AI summary
The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating cancer in a subject having clinical signs of bone marrow homing of myeloid cells, including neutropenia, isolated neutropenia, a low percentage of peripheral blood blasts with or without a high percentage of bone marrow blasts, and/or a low ratio of peripheral blood blasts to bone marrow blasts, with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on hematological characteristics indicating bone marrow homing of myeloid cells.